

section 502 of the Act relating to misbranding and the prohibition in section 301(d) of the Act against the introduction or delivery for introduction into interstate commerce of unapproved new drugs in violation of section 505(a) of the Act.

(c) *Warnings.* The labeling of the product contains the following warnings under the heading “Warnings”:

(1) “The recommended dose of this product contains about as much caffeine as a cup of coffee. Limit the use of caffeine-containing medications, foods, or beverages while taking this product because too much caffeine may cause nervousness, irritability, sleeplessness, and, occasionally, rapid heart beat.”

(2) “For occasional use only. Not intended for use as a substitute for sleep. If fatigue or drowsiness persists or continues to recur, consult a” (select one of the following: “physician” or “doctor”).

(3) “Do not give to children under 12 years of age.”

(d) *Directions.* The labeling of the product contains the following information under the heading “Directions”: Adults and children 12 years of age and over: Oral dosage is 100 to 200 milligrams not more often than every 3 to 4 hours.

## PART 341—COLD, COUGH, ALLERGY, BRONCHODILATOR, AND ANTI-ASTHMATIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE

### Subpart A—General Provisions

Sec.

341.1 Scope.

341.3 Definitions.

### Subpart B—Active Ingredients

341.12 Antihistamine active ingredients.

341.14 Antitussive active ingredients.

341.16 Bronchodilator active ingredients.

341.18 Expectorant active ingredient.

341.20 Nasal decongestant active ingredients.

341.40 Permitted combinations of active ingredients.

### Subpart C—Labeling

341.70 Labeling of OTC drug products containing ingredients that are used for

treating concurrent symptoms (in either a single-ingredient or combination drug product).

341.72 Labeling of antihistamine drug products.

341.74 Labeling of antitussive drug products.

341.76 Labeling of bronchodilator drug products.

341.78 Labeling of expectorant drug products.

341.80 Labeling of nasal decongestant drug products.

341.85 Labeling of permitted combinations of active ingredients.

341.90 Professional labeling.

AUTHORITY: 21 U.S.C. 321, 351, 352, 353, 355, 360, 371.

EDITORIAL NOTE: Nomenclature changes to part 341 appear at 69 FR 13717, Mar. 24, 2004.

## Subpart A—General Provisions

### § 341.1 Scope.

(a) An over-the-counter cold, cough, allergy, bronchodilator, or anti-asthmatic drug product in a form suitable for oral, inhalant, or topical administration is generally recognized as safe and effective and is not misbranded if it meets each of the conditions in this part and each of the general conditions established in § 330.1.

(b) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21 unless otherwise noted.

[51 FR 35339, Oct. 2, 1986]

### § 341.3 Definitions.

As used in this part:

(a) *Bronchodilator drug.* A drug used to overcome spasms that cause narrowing of the bronchial air tubes, such as in the symptomatic treatment of the wheezing and shortness of breath of asthma.

(b) *Oral antitussive drug.* A drug that either is taken by mouth or is dissolved in the mouth in the form of a lozenge and acts systemically to relieve cough.

(c) *Topical antitussive drug.* A drug that relieves cough when inhaled after being applied topically to the throat or chest in the form of an ointment or from a steam vaporizer, or when dissolved in the mouth in the form of a lozenge for a local effect.